Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Renal Cell 26Kidney Neoplasms 21Melanoma 20Leukemia 17Leukemia, Myeloid, Chronic-Phase 15Multiple Myeloma 12Lymphoma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasms, Plasma Cell 8Lymphoma, Follicular 7Pancreatic Neoplasms 6Waldenstrom Macroglobulinemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Neoplasms 4Lymphoma, Mantle-Cell 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Immunoglobulin Light-chain Amyloidosis 4Blast Crisis 4Urinary Bladder Neoplasms 3Primary Myelofibrosis 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3

Interventions

Surveys and Questionnaires 1Lymph Node Excision 1Interferon-alpha 1Imiquimod 13-ingenyl angelate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Facies × Interferon-alpha × Clear all
NCT00581425 2013-01-25

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

The University of Texas Health Science Center, Houston

Phase 4 Completed
49 enrolled
Dermatologic

Carcinoma, Basal Cell, Facies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡